1-3 of 3
Alissa Nelson
Close
Sort by
Journal Articles

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Elspeth M. Beauchamp, Sameem M. Abedin, Sara G. Radecki, Mariafausta Fischietti, Ahmet Dirim Arslan, Gavin T. Blyth, Angela Yang, Connor Lantz, Alissa Nelson, Young Ah Goo, Imo Akpan, Elizabeth A. Eklund, Olga Frankfurt, Eleanor N. Fish, Paul M. Thomas, Jessica K. Altman, Leonidas C. Platanias
Journal: Blood
Blood (2019) 133 (11): 1171–1185.
https://doi.org/10.1182/blood-2018-08-870089
Published: 2019
Includes: Supplemental data
Journal Articles

A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.

Ravi Vij, MD, Alissa Nelson, Geoffrey L. Uy, MD, Camille Abboud, Peter Westervelt, MD, PhD, Amanda F Cashen, MD, Stockerl-Goldstein Keith, MD, Kathryn M Trinkhaus, Ph.D., John F. DiPersio, MD, PhD, Todd A Fehniger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 842.
https://doi.org/10.1182/blood.V114.22.842.842
Published: 2009
Journal Articles

Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.

Todd A. Fehniger, Alissa Nelson, Kathryn Trinkaus, Camille N. Abboud, Amanda F. Cashen, John F. DiPersio, Timothy A. Graubert, Timothy J. Ley, Michael H. Tomasson, Geoffrey L. Uy, Matthew J. Walter, Peter Westervelt, Ravi Vij
Journal: Blood
Blood (2007) 110 (11): 916.
https://doi.org/10.1182/blood.V110.11.916.916
Published: 2007